These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36482451)

  • 1. A systematic comparison of different composite measures (DAS 28, CDAI, SDAI, and Boolean approach) for determining treatment effects on low disease activity and remission in rheumatoid arthritis.
    Janke K; Kiefer C; McGauran N; Richter B; Krause D; Wieseler B
    BMC Rheumatol; 2022 Dec; 6(1):82. PubMed ID: 36482451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis.
    Messelink MA; den Broeder AA; Marinelli FE; Michgels E; Verschueren P; Aletaha D; Tekstra J; Welsing PMJ
    RMD Open; 2023 Apr; 9(2):. PubMed ID: 37116986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.
    Aletaha D; Wang X; Zhong S; Florentinus S; Monastiriakos K; Smolen JS
    Semin Arthritis Rheum; 2020 Apr; 50(2):276-284. PubMed ID: 31590930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients.
    Dhaon P; Das SK; Srivastava R; Dhakad U
    Int J Rheum Dis; 2018 Nov; 21(11):1933-1939. PubMed ID: 28608433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
    Smolen JS; Aletaha D
    Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliability and validity of CDAI and SDAI indices in comparison to DAS-28 index in Moroccan patients with rheumatoid arthritis.
    Slama IB; Allali F; Lakhdar T; El Kabbaj S; Medrare L; Ngeuleu A; Rkain H; Hajjaj-Hassouni N
    BMC Musculoskelet Disord; 2015 Sep; 16():268. PubMed ID: 26420567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points.
    Mack ME; Hsia E; Aletaha D
    Arthritis Rheumatol; 2017 Mar; 69(3):518-528. PubMed ID: 27696724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of rheumatoid arthritis composite disease activity indices and residual activity in a Brazilian multicenter study- REAL study.
    Santos IA; Donizeti Ribeiro de Oliveira R; Couto Luna Almeida S; Vargas-Santos AB; Balbino Chaves Amorim R; Monteiro Gomides AP; de Albuquerque CP; Barros Bertolo M; Brandão Resende Guimarães MF; da Costa Pinto MR; Gomes Resende G; Dalva Neubarth Giorgi R; de Carvalho Saciloto N; Radominski SC; Borghi FM; Rossi Bonfiglioli K; Carrico da Silva H; de Fatima L da Cunha Sauma M; Alves Pereira I; Werner de Castro GR; Viegas Brenol C; Machado Xavier R; Maria Henrique Mota L; Louzada-Junior P; da Rocha Castelar-Pinheiro G
    PLoS One; 2022; 17(9):e0273789. PubMed ID: 36174077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Reactive Oxygen Metabolites as a Predictor of Clinical Disease Activity Index, Simplified Disease Activity Index, and Boolean Remissions in Rheumatoid Arthritis Patients Treated With Biologic Agents.
    Nakajima A; Terayama K; Sonobe M; Akatsu Y; Saito J; Norimoto M; Taniguchi S; Kubota A; Aoki Y; Nakagawa K
    Cureus; 2021 Nov; 13(11):e19759. PubMed ID: 34938634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.
    Schoels M; Alasti F; Smolen JS; Aletaha D
    Arthritis Res Ther; 2017 Jul; 19(1):155. PubMed ID: 28676129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI.
    Gaujoux-Viala C; Mouterde G; Baillet A; Claudepierre P; Fautrel B; Le Loët X; Maillefert JF
    Joint Bone Spine; 2012 Mar; 79(2):149-55. PubMed ID: 21680221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive therapy and remissions in rheumatoid arthritis: a systematic review.
    Hughes CD; Scott DL; Ibrahim F;
    BMC Musculoskelet Disord; 2018 Oct; 19(1):389. PubMed ID: 30376836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis.
    Klarenbeek NB; Koevoets R; van der Heijde DM; Gerards AH; Ten Wolde S; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
    Ann Rheum Dis; 2011 Oct; 70(10):1815-21. PubMed ID: 21813548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DAS28, CDAI and SDAI cut-offs do not translate the same information: results from the Rheumatic Diseases Portuguese Register Reuma.pt.
    Martins FM; da Silva JA; Santos MJ; Vieira-Sousa E; Duarte C; Santos H; Costa JA; Pimentel-Santos FM; Cunha I; Cunha Miranda L; Nóvoa T; Cruz M; Bernardes M; Araujo D; Pereira Silva JA; Silva JC; Branco JC; Gomes JA; Faustino A; Fonseca JE; Canhão H
    Rheumatology (Oxford); 2015 Feb; 54(2):286-91. PubMed ID: 25173347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Advantage of Attaining Index-Based Remission Prior to Composite Remission in Treating Rheumatoid Arthritis.
    Yoshii I; Chijiwa T; Sawada N
    Reumatol Clin (Engl Ed); 2022 Dec; 18(10):574-579. PubMed ID: 36435555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis.
    Futó G; Somogyi A; Szekanecz Z
    Clin Rheumatol; 2014 May; 33(5):623-9. PubMed ID: 24599677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry.
    Koh JH; Lee Y; Kim HA; Kim J; Shin K
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221096363. PubMed ID: 35586514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are There Sex-Related Differences in the Effectiveness of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients?
    Martinez-Molina C; Feliu A; Park HS; Juanes A; Diaz-Torne C; Vidal S; Corominas H
    J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673626
    [No Abstract]   [Full Text] [Related]  

  • 19. Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: a secondary analysis of clinical trial data from children with polyarticular-course juvenile idiopathic arthritis.
    Ringold S; Chon Y; Singer NG
    Arthritis Rheum; 2009 Dec; 60(12):3776-83. PubMed ID: 19950286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to Define Boolean Low Disease Activity in Rheumatoid Arthritis: Experience from a Large Real-world Cohort.
    Xie W; Li G; Huang H; Zhang Z
    Rheumatol Ther; 2021 Mar; 8(1):289-301. PubMed ID: 33355913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.